Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.20 | 0.98 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.79 | 5.32 | 16.14 | 89.92 | 13.62 | 7.30 | 3.60 | 2.44 | 5.45 | 4.05 | 3.57 | 6.96 | 8.37 | 3.91 | 18.11 | 2.03 | 0.72 | 7.33 | 3.84 | 33.90 | 42.09 |
| — | -27.2% | +348.3% | +3581.6% | +149.7% | +80.5% | +0.8% | -64.9% | -34.8% | +3.4% | -80.3% | +243.5% | +1068.4% | -46.6% | +371.8% | -94.0% | -98.3% | -94.3% | -96.6% | -73.4% | -66.9% | |
| P/B Ratio | 1.32 | 2.31 | 1.11 | 1.15 | 0.78 | 2.23 | 1.53 | 1.23 | 1.90 | 2.40 | 2.54 | 3.44 | 3.01 | 2.42 | 2.67 | 1.98 | 1.70 | 2.69 | 2.44 | 3.85 | 4.27 |
| — | +3.4% | -27.2% | -6.6% | -58.7% | -7.0% | -39.8% | -64.3% | -36.9% | -1.1% | -4.9% | +74.0% | +77.4% | -10.0% | +9.6% | -48.6% | -60.3% | -44.6% | -16.4% | +25.2% | +48.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.77 | — | 0.73 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.80 | 0.33 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 6.03 | 0.33 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.5% | — | 100.0% | -7.9% | 100.0% | 80.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 64.4% | 35.5% | 83.2% | -181.9% | -41.0% | -756.1% | -430.4% |
| — | — | 0.0% | -107.9% | 0.0% | -19.5% | 0.0% | 0.0% | 0.0% | 0.0% | +55.2% | +181.5% | +20.2% | +155.0% | +257.3% | +104.7% | +119.3% | +89.7% | +98.1% | +66.4% | +52.2% | |
| Operating Margin | -111.5% | -50.2% | -863.3% | -4882.0% | -1016.1% | -96.3% | -47.4% | -57.3% | -159.0% | -27.7% | -46.0% | -93.3% | -72.9% | -44.5% | -526.4% | 18.4% | 75.8% | -275.3% | -81.5% | -960.7% | -649.7% |
| — | +47.9% | -1721.6% | -8425.0% | -539.0% | -248.0% | -3.1% | +38.6% | -118.3% | +37.9% | +91.3% | -607.6% | -196.2% | +83.8% | -545.7% | +101.9% | +111.7% | +87.5% | +97.0% | +64.6% | +53.2% | |
| Net Margin | -97.9% | 9.7% | -803.8% | -4420.3% | -943.8% | -78.4% | -37.5% | -47.9% | -142.9% | -17.8% | -37.4% | -82.3% | -46.7% | -37.4% | -499.6% | 63.2% | 73.2% | -263.8% | -79.6% | -975.8% | -667.3% |
| — | +112.4% | -2046.1% | -9126.9% | -560.6% | -340.9% | -0.0% | +41.8% | -206.1% | +52.4% | +92.5% | -230.1% | -163.8% | +85.8% | -527.7% | +106.5% | +111.0% | +88.1% | +97.1% | +63.2% | +52.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.9% | 1.0% | -13.1% | -13.3% | -13.3% | -5.9% | -4.0% | -5.9% | -11.9% | -2.7% | -6.6% | -9.9% | -4.2% | -5.7% | -17.1% | 16.9% | 56.4% | -22.3% | -12.1% | -24.8% | -15.9% |
| — | +117.6% | -231.6% | -124.4% | -11.1% | -122.5% | +40.1% | +40.0% | -184.7% | +53.8% | +61.5% | -158.4% | -107.4% | +74.3% | -41.0% | +168.3% | +455.6% | -16.4% | +26.8% | -64.7% | -67.9% | |
| ROA | -21.4% | 0.8% | -10.1% | -10.4% | -10.5% | -4.5% | -2.9% | -4.2% | -8.4% | -1.8% | -4.3% | -6.3% | -2.6% | -3.7% | -11.7% | 11.0% | 31.5% | -11.2% | -6.4% | -13.9% | -9.3% |
| — | +117.7% | -253.6% | -150.6% | -25.1% | -150.0% | +32.8% | +34.1% | -218.1% | +50.2% | +63.4% | -157.4% | -108.4% | +67.3% | -83.6% | +179.1% | +437.5% | +8.7% | +45.9% | -18.4% | -20.0% | |
| ROIC | -277.1% | -254.6% | -529.8% | -370.8% | -60.0% | -18.8% | -14.4% | -27.4% | -57.8% | -57.0% | — | -188.3% | -76.0% | -218.3% | -292.5% | 288.5% | — | — | — | — | — |
| — | -1254.0% | -3580.0% | -1251.0% | -3.8% | +67.0% | — | +85.4% | +23.9% | +73.9% | — | -165.3% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.11 | 0.13 | 0.13 | 0.12 | 0.12 | 0.12 | 0.18 | 0.12 | 0.11 | 0.12 | 0.12 | 0.11 | 0.18 | 0.11 | 0.10 | 0.35 | 0.65 | 0.58 | 0.37 | 0.30 |
| — | -6.6% | +14.4% | -31.3% | -1.4% | +3.0% | -2.3% | +50.9% | +9.2% | -38.6% | +5.8% | +20.0% | -69.1% | -71.9% | -80.4% | -73.1% | +15.7% | +150.6% | +158.7% | +93.0% | +479.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.16 | 0.78 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.64 | 6.68 | 5.88 | 6.31 | 6.64 | 7.86 | 5.90 | 5.64 | 4.67 | 4.76 | 3.78 | 3.26 | 4.72 | 4.49 | 4.26 | 4.71 | 3.18 | 3.25 | 3.14 | 3.05 | 3.81 |
| — | -15.0% | -0.4% | +11.8% | +42.1% | +65.1% | +56.0% | +73.3% | -0.9% | +6.2% | -11.3% | -30.9% | +48.5% | +37.9% | +35.7% | +54.6% | -16.6% | -8.7% | -49.2% | -65.4% | -59.7% | |
| Quick Ratio | 6.64 | 6.68 | 5.88 | 6.31 | 6.64 | 7.86 | 5.90 | 5.64 | 4.67 | 4.76 | 3.78 | 3.26 | 4.72 | 4.49 | 4.26 | 4.71 | 3.18 | 3.25 | 3.14 | 3.05 | 3.81 |
| — | -15.0% | -0.4% | +11.8% | +42.1% | +65.1% | +56.0% | +73.3% | -0.9% | +6.2% | -11.3% | -30.9% | +48.5% | +37.9% | +35.7% | +54.6% | -16.6% | -8.7% | -49.2% | -65.4% | -59.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | -2860.25 | -965.70 | — | 19.86 | 153.74 | -48.11 | -30.34 | -70.17 | -53.17 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARCT stock.
Arcturus Therapeutics Holdings Inc.'s current P/E is -3.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcturus Therapeutics Holdings Inc.'s current operating margin is -111.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcturus Therapeutics Holdings Inc.'s business trajectory between earnings reports.